{
  "guid": "3f7d4ad7-2db8-4bdf-92dd-40f80f11860a",
  "title": "A Covid Testing Crisis, Again",
  "description": "<p>By the end of last year, if you needed a coronavirus test, you could get one. But when vaccines arrived, focus shifted.</p><p>Many of the vaccinated felt like they didn’t need tests and demand took a nosedive. Testing sites were closed or converted into vaccination sites. And Abbott Laboratories, a major test manufacturer, wound up destroying millions.</p><p>However, with the surge of the new Omicron variant, which is less susceptible to vaccines, demand for testing is back — and it is outstripping supply.</p><p>Guest: <a href=\"https://www.nytimes.com/by/sheryl-gay-stolberg?smid=pc-thedaily\">Sheryl Gay Stolberg</a>, a Washington correspondent, covering health policy for The New York Times.</p><p><a href=\"https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily\">Sign up here</a> to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, <a href=\"https://www.nytimes.com/newsletters/the-daily?module=inline\">subscribe to our newsletter</a>. </p><p>Background reading: </p><ul><li>President Biden came into office vowing to make coronavirus testing cheap and accessible, but<a href=\"https://www.nytimes.com/2021/12/17/us/politics/us-covid-tests-omicron.html\"> matching supply with demand has been a persistent problem</a>.</li></ul><p>For more information on today’s episode, visit <a href=\"http://nytimes.com/thedaily?smid=pc-thedaily\">nytimes.com/thedaily</a>. Transcripts of each episode will be made available by the next workday. </p>\n",
  "pubDate": "Wed, 22 Dec 2021 10:50:00 +0000",
  "author": "thedaily@nytimes.com (The New York Times)",
  "link": "https://www.nytimes.com/the-daily",
  "content:encoded": "<p>By the end of last year, if you needed a coronavirus test, you could get one. But when vaccines arrived, focus shifted.</p><p>Many of the vaccinated felt like they didn’t need tests and demand took a nosedive. Testing sites were closed or converted into vaccination sites. And Abbott Laboratories, a major test manufacturer, wound up destroying millions.</p><p>However, with the surge of the new Omicron variant, which is less susceptible to vaccines, demand for testing is back — and it is outstripping supply.</p><p>Guest: <a href=\"https://www.nytimes.com/by/sheryl-gay-stolberg?smid=pc-thedaily\">Sheryl Gay Stolberg</a>, a Washington correspondent, covering health policy for The New York Times.</p><p><a href=\"https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily\">Sign up here</a> to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, <a href=\"https://www.nytimes.com/newsletters/the-daily?module=inline\">subscribe to our newsletter</a>. </p><p>Background reading: </p><ul><li>President Biden came into office vowing to make coronavirus testing cheap and accessible, but<a href=\"https://www.nytimes.com/2021/12/17/us/politics/us-covid-tests-omicron.html\"> matching supply with demand has been a persistent problem</a>.</li></ul><p>For more information on today’s episode, visit <a href=\"http://nytimes.com/thedaily?smid=pc-thedaily\">nytimes.com/thedaily</a>. Transcripts of each episode will be made available by the next workday. </p>\n",
  "enclosure": "",
  "itunes:title": "A Covid Testing Crisis, Again",
  "itunes:author": "The New York Times",
  "itunes:duration": "00:31:45",
  "itunes:summary": "By the end of last year, if you needed a coronavirus test, you could get one. But when vaccines arrived, focus shifted.\n\nMany of the vaccinated felt like they didn’t need tests and demand took a nosedive. Testing sites were closed or converted into vaccination sites. And Abbott Laboratories, a major test manufacturer, wound up destroying millions.\n\nHowever, with the surge of the new Omicron variant, which is less susceptible to vaccines, demand for testing is back — and it is outstripping supply.\n\nGuest: Sheryl Gay Stolberg, a Washington correspondent, covering health policy for The New York Times.",
  "itunes:subtitle": "By the end of last year, if you needed a coronavirus test, you could get one. But when vaccines arrived, focus shifted.\n\nMany of the vaccinated felt like they didn’t need tests and demand took a nosedive. Testing sites were closed or converted into vaccination sites. And Abbott Laboratories, a major test manufacturer, wound up destroying millions.\n\nHowever, with the surge of the new Omicron variant, which is less susceptible to vaccines, demand for testing is back — and it is outstripping supply.\n\nGuest: Sheryl Gay Stolberg, a Washington correspondent, covering health policy for The New York Times.",
  "itunes:explicit": "no",
  "itunes:episodeType": "full"
}